phosphorylated tau in CSF

From Aaushi
Jump to navigation Jump to search

Introduction

Also see:

Clinical significance

Increases

More general terms

Component of

References

  1. Jump up to: 1.0 1.1 Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: A cross-sectional study. Lancet 2020 Jun 27; 395:1988. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32593336 Free PMC article https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30689-9/fulltext
    Head E, Ances B. Biomarkers in Down syndrome can help us understand Alzheimer's disease. Lancet 2020 Jun 27; 395:1951 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32593327 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30916-8/fulltext
  2. Jump up to: 2.0 2.1 Karikari TK et al Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimers & Dementia 2020. Nov 30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33252199 https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12236
  3. Jump up to: 3.0 3.1 Therriault J, Vermeiren M, Servaes S et al Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol. Published online December 12, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36508198 https://jamanetwork.com/journals/jamaneurology/fullarticle/2799180
  4. Jump up to: 4.0 4.1 4.2 George J Alzheimer's Test Detects Tau Pathology Before Tangles Form. Detecting soluble tau assemblies early may improve Alzheimer's treatment outcomes. MedPage Today February 11, 2025 https://www.medpagetoday.com/neurology/alzheimersdisease/114181
    Islam T, Hill E, Abrahamson EE et al Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's disease. Nat Med. 2025 Feb 10. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39930142 https://www.nature.com/articles/s41591-024-03400-0